On Friday, DexCom, Inc. (NASDAQ: DXCM) +2.53% in trading session and finally closed at $146.99. The firm after opening the first trading session at $142.11 Over the one year trading period, the stock has an above price of $157.50 and it’s below is recorded at $92.23. The company has a market cap of $13.383B. The company most recent volume stood at 571,734 shares as compared to its average volume of 1,215,244 shares.
DexCom, Inc. (NASDAQ: DXCM) recently stated its financial results as of and for the quarter ended March 31, 2019.
Revenue: In the first quarter of 2019, worldwide revenue grew 52% to $280.5M, up from $184.4M in the first quarter of 2018. The growth was driven by increasing volumes across all channels in conjunction with the rising global awareness of the benefits of real-time CGM.
Gross Profit: Gross profit totaled $168.8M or 60.2% of sales for the first quarter of 2019, contrast to $118.9M or 64.5% of sales in the first quarter of 2018.
Operating Loss: GAAP operating loss for the first quarter of 2019 was $14.4M, contrast to a GAAP operating loss of $30.7M for the first quarter of 2018.
Non-GAAP operating loss* for the first quarter of 2019 was $7.6M, contrast to a non-GAAP operating loss of $28.7M for the first quarter of 2018. The first quarter 2019 non-GAAP amount excludes $6.4M of business transition and related costs and the first quarter 2018 non-GAAP amount excludes $2.0M of such costs.
Net Loss and Net Loss per Share: GAAP net loss was $26.9M, or $0.30 per share, for the first quarter of 2019, contrast to a GAAP net loss of $24.2M, or $0.28 per share, for the same quarter of 2018.
Non-GAAP net loss* was $4.6M, or $0.05 per share, for the first quarter of 2019, contrast to a non-GAAP net loss of $26.3M, or $0.30 per diluted share, for the same quarter of 2018. The first quarter 2019 non-GAAP amount excludes $6.4M of business transition costs, $11.3M of non-cash interest expense related to Dexcom’s senior convertible notes, and a $4.2M loss related to equity investments.
Cash and Liquidity: As of March 31, 2019, Dexcom held $1.358B in cash and marketable securities and maintained full availability on its $200.0M revolving credit facility.